Boehringer Ingelheim to evaluate BI754091 with Amal's ATP128

2 May 2019
boehringer_headquarters_flags_large

Geneva, Switzerland-based biotech Amal Therapeutics has entered into a collaborative agreement with German family-owned pharma major Boehringer Ingelheim.

Amal will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128, with Boehringer’s anti-PD1 compound, BI754091, in microsatellite stable (MSS) patients with stage IV colorectal cancer. The KISIMA-01 study will begin in the second half of 2019.

Amal’s lead candidate, ATP128, is a chimeric recombinant protein designed using Amal’s proprietary vaccine technology platform, KISIMA. ATP128 comprises of a cell penetrating peptide (CPP) for antigen delivery, a TLR peptide agonist for self-adjuvanticity and a multiple antigenic domain (Mad). ATP128 is designed to treat colorectal cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology